Navigation Links
Drug dramatically reduces nausea and vomiting in bone marrow transplant patients
Date:3/1/2010

Bone marrow transplant patients say two of the most debilitating side effects of the treatment are nausea and vomiting caused by chemotherapy and radiation.

But a Loyola University Health System study has found the drug aprepitant can dramatically reduce both nausea and vomiting when combined with other anti-nausea drugs.

Seventy-three percent of patients receiving aprepitant experienced no vomiting during the study period, compared with 23 percent of patients who received a placebo. (Both groups also received a standard anti-nausea drug.) Forty-nine percent of aprepitant patients experienced no vomiting and little or no nausea, compared with 15 percent of the placebo group.

Dr. Patrick Stiff presenting findings at the 2010 BMT Tandem Meetings in Orlando, Fla. His study received a Best Abstract Award from the Center for International Blood & Marrow Transplant Research, one of two organizations sponsoring the meetings. The other sponsor is the American Society for Blood and Marrow Transplantation.

Aprepitant (brand name Emend) was approved by the Food and Drug Administration in 2003 to help prevent and control vomiting and nausea from chemotherapy. However, there previously had been only a few small studies on the benefit of aprepitant in bone marrow transplant patients, who receive higher doses of chemotherapy than most other cancer patients. "We did not know how effective aprepitant would be for bone marrow transplant patients," Stiff said. "We now believe this should become a standard part of patients' care."

Bone marrow transplant patients say nausea/vomiting is the second-worst side effect of the treatment. (The only thing worse is mouth and throat sores.) Patients can throw up three to five times a day for a week or longer.

Other anti-nausea/vomiting drugs work by blocking signals from the stomach. But signals from the brain still can make a patient queasy. Aprepitant acts to block nausea/vomiting signals from the brain, and is taken together with drugs that block signals from the stomach.

In Stiff's Phase III, blinded, prospective study, 90 bone marrow transplant patients were randomly assigned to receive aprepitant and 89 patients were randomly assigned to receive a placebo.

The aprepitant group did not experience significantly more side effects than the placebo group. Aprepitant also had no meaningful impact on the success of the transplant, relapse rates or overall survival.

Bone marrow transplants are used to treat such diseases as leukemia, lymphoma and Hodgkin's disease. Patients receive high-dose chemotherapy to kill cancer cells. Chemotherapy also kills immune system cells. So patients receive infusions of donated bone marrow cells that develop into healthy new immune cells.

Loyola has the largest bone marrow transplant program in Illinois. "One of the main themes of our research is to make bone marrow transplants more patient-friendly," Stiff said. "Transplants are much more comfortable and easier to tolerate than they were a few years ago."

Previous studies at Loyola were instrumental in showing the effectiveness of the drug palifermin in preventing mouth and throat sores in transplant patients.


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. New Case Study Details How an Illinois Hospital Created a Safe Lifting Team that Dramatically Reduced Injuries, Increased Staff Satisfaction
2. Giving emergency nurses aromatherapy massages with music dramatically reduced stress levels
3. Giving emergency nurses aromatherapy massages with music dramatically reduced stress levels
4. Early intervention dramatically improves outcomes for new dialysis patients
5. Technology can Dramatically Reduce Billions of Dollars in Medicaid, Medicare Fraud
6. New Research Shows Nutrition Programs Targeting Pregnancy and First 24 Months of Life Dramatically Improve Child Survival and Overall Health
7. Daily exercise dramatically lowers mens death rates
8. Hospital Testing for Drug-Resistant Infections Dramatically Lowers Mortality Rates and Costs
9. Use of Methamphetamine Among U.S. Workers and Job Applicants Drops 22 Percent in 2007 and Cocaine Use Slows Dramatically, Reports Quest Diagnostics
10. New survey shows allergies dramatically impact sufferers moods and how they feel about themselves
11. New study finds glamorization of drugs in rap music jumped dramatically over 2 decades
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... OR (PRWEB) , ... January 16, 2017 , ... ... author, editor, attorney, science teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading ... Kent Heckenlively to her nationally syndicated radio program, The Sharon Kleyne Hour Power ...
(Date:1/16/2017)... IL (PRWEB) , ... January 16, 2017 , ... ... (iaedp) organized to provide first-quality education and high-level training standards to an international ... spectrum of eating disorder problems. As a way to further its mission at ...
(Date:1/16/2017)... ... January 16, 2017 , ... San Francisco dentist, Dr. ... the latest in 3-D scanning device which is capable of taking digital impressions of ... in dentistry, such as CAD CAM restorations , in terms of speed, efficiency ...
(Date:1/16/2017)... , ... January 16, 2017 , ... NexTec Group has ... group of 100 organizations honored for their accomplishments in the field of midmarket financial ... industry leadership and recognition, and innovation. Selection is not based on revenue and those ...
(Date:1/15/2017)... CINCINNATI, Ohio (PRWEB) , ... January 15, 2017 ... ... their applications, Gensuite’s Community Outreach is a program that strives to better communities ... in each global locations’ community. It also provides the opportunity for team members ...
Breaking Medicine News(10 mins):
(Date:1/14/2017)... , Jan. 14, 2017  Johnson & Weaver, LLP ... of purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ... through October 31, 2016 (the "Class Period"). Zimmer ... and markets orthopaedic reconstructive products, such as knee and hip ... ...
(Date:1/13/2017)... , January 13, 2017 Constant research ... AIDS will collectively contribute to the demand for western blotting ... a value of US$ 551.0 Mn by 2016 end. Developing ... the most lucrative markets for western blotting, whereas ... globally. ...
(Date:1/13/2017)... YORK , January 13, 2017 ... equities to see how they have fared at yesterday,s ... ), Galena Biopharma Inc. (NASDAQ: GALE ), ... These companies harness cellular and biomolecular processes to develop ... reduce our environmental footprint, feed the hungry, use less ...
Breaking Medicine Technology: